AP3413A - Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension - Google Patents

Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension

Info

Publication number
AP3413A
AP3413A AP2013006753A AP2013006753A AP3413A AP 3413 A AP3413 A AP 3413A AP 2013006753 A AP2013006753 A AP 2013006753A AP 2013006753 A AP2013006753 A AP 2013006753A AP 3413 A AP3413 A AP 3413A
Authority
AP
ARIPO
Prior art keywords
glaucoma
adenosine
agonists
treatment
ocular hypertension
Prior art date
Application number
AP2013006753A
Other languages
English (en)
Other versions
AP2013006753A0 (en
Inventor
Daniel Meibom
Andreas Knorr
Georges Von Degenfeld
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of AP2013006753A0 publication Critical patent/AP2013006753A0/xx
Application granted granted Critical
Publication of AP3413A publication Critical patent/AP3413A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AP2013006753A 2010-09-02 2011-08-29 Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension AP3413A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10175151 2010-09-02
PCT/EP2011/064829 WO2012028585A1 (fr) 2010-09-02 2011-08-29 Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire

Publications (2)

Publication Number Publication Date
AP2013006753A0 AP2013006753A0 (en) 2013-02-28
AP3413A true AP3413A (en) 2015-09-30

Family

ID=44582992

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013006753A AP3413A (en) 2010-09-02 2011-08-29 Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension

Country Status (30)

Country Link
US (3) US20120058983A1 (fr)
EP (1) EP2611415B1 (fr)
JP (1) JP5875585B2 (fr)
KR (1) KR20140091457A (fr)
CN (1) CN103249400B (fr)
AP (1) AP3413A (fr)
AU (1) AU2011298430B2 (fr)
BR (1) BR112013005224A2 (fr)
CA (1) CA2809700A1 (fr)
CL (2) CL2013000599A1 (fr)
CR (1) CR20130094A (fr)
CY (1) CY1117458T1 (fr)
DK (1) DK2611415T3 (fr)
EA (1) EA028411B1 (fr)
ES (1) ES2570659T3 (fr)
HR (1) HRP20160532T1 (fr)
HU (1) HUE027295T2 (fr)
MA (1) MA34489B1 (fr)
MX (1) MX2013002396A (fr)
MY (1) MY160383A (fr)
NZ (1) NZ607624A (fr)
PH (1) PH12013500416A1 (fr)
PL (1) PL2611415T3 (fr)
RS (1) RS54743B1 (fr)
SG (1) SG187974A1 (fr)
SI (1) SI2611415T1 (fr)
TW (1) TWI516266B (fr)
UA (1) UA111947C2 (fr)
WO (1) WO2012028585A1 (fr)
ZA (1) ZA201302340B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861009A1 (fr) 2012-01-26 2013-08-01 Inotek Pharmaceuticals Corporation Polymorphes anhydres de nitrate de methyle [(2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yle)-3,4-dihydroxytetrahydrofuran-2-yle)] et processus de preparation de ceux-ci
WO2015089105A1 (fr) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Formulations en poudre d'inhibiteur pde5 et procédés y associés
MA39101A1 (fr) * 2013-12-12 2017-08-31 Bayer Pharma AG Agonistes a1 de l'adénosine utilisés comme médicaments contre les maladies des reins
SG11201605532YA (en) * 2014-01-10 2016-08-30 Santen Pharmaceutical Co Ltd Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
ES2744227T3 (es) * 2015-05-06 2020-02-24 Bayer Pharma AG Procedimiento para la preparación de monoclorhidrato de L-alanil-L-alaninato de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridin-4-il]fenoxi}etilo
WO2017137528A1 (fr) 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Agoniste du récepteur a1 de l'adénosine pour utilisation dans le traitement de l'état de mal épileptique
CN112545983A (zh) * 2020-12-18 2021-03-26 合肥中龙神力动物药业有限公司 一种复方硫酸新霉素滴眼液及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007036076A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102008062561A1 (de) * 2008-12-16 2010-06-24 Maxon Motor Ag Bausatz für einen Elektromotor mit einem Drehwinkelgeber

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052510A (en) 1974-12-18 1977-10-04 Sandoz, Inc. 4-alkyl-2,6-di(secondary or tertiary alkylamino) pyridines, compositions thereof and methods for treating diabetes and obesity
TW299333B (fr) 1992-12-29 1997-03-01 Takeda Pharm Industry Co Ltd
DE4334919A1 (de) * 1993-10-13 1995-04-20 Liedtke Pharmed Gmbh Grenzwertig wirksame Arzneiformen mit Betablockern
NZ284846A (en) 1994-06-16 1998-12-23 Pfizer 1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof
DE4430638A1 (de) 1994-08-29 1996-03-07 Bayer Ag Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel
JPH09132529A (ja) 1995-11-09 1997-05-20 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
EP0876379A1 (fr) 1996-01-17 1998-11-11 Novo Nordisk A/S Derives de 1,2,4-thiadiazine fusionnee et de 1,4-thiazine fusionnee, leur preparation et utilisation
JP4431638B2 (ja) 1996-01-29 2010-03-17 アメリカ合衆国 ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
JPH10324687A (ja) 1997-02-19 1998-12-08 Nippon Soda Co Ltd ピロール化合物、製法および農園芸用殺菌剤
WO1998054139A1 (fr) 1997-05-30 1998-12-03 Basf Aktiengesellschaft Procede de fabrication de thiopyridines substituees
JP2001510195A (ja) 1997-07-16 2001-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合化１，２，４−チアジアジン誘導体、その調製及び使用
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
KR100521735B1 (ko) 2000-02-25 2005-10-17 에프. 호프만-라 로슈 아게 아데노신 수용체 조절인자
PL359416A1 (en) 2000-07-18 2004-08-23 Yamanouchi Pharmaceutical Co, Ltd. Medicine comprising dicyanopyridine derivative
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
JP2004515543A (ja) 2000-12-11 2004-05-27 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 有害無脊椎動物を防除するためのキナゾリノン類およびピリジニルピリミジノン類
ES2257461T3 (es) 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10134481A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
JP2003183254A (ja) 2001-12-20 2003-07-03 Yamanouchi Pharmaceut Co Ltd ２−アシルアミノ−３，５−ジシアノピリジン誘導体又はその塩
US7304061B2 (en) 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP1388342A1 (fr) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Dérivés de cycloalkenylamine condensé avec un hététoaryle et acylé et leur utilisation comme produits pharmaceutiques
BR0313396A (pt) 2002-08-12 2005-06-28 Sugen Inc 3-pirrolil-piridopirazóis e 3-pirrolil-indazóis, como inibidores de quinase
BR0317183A (pt) 2002-12-12 2005-11-01 Pharmacia Corp Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
AR042667A1 (es) 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CA2539707C (fr) 2003-09-23 2011-08-09 Merck & Co., Inc. Inhibiteurs des canaux potassiques a la quinoleine
WO2005046603A2 (fr) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Composes pyridiniques
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
AU2005257486A1 (en) 2004-06-25 2006-01-05 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as CRF antagonists
DE102004032651A1 (de) * 2004-07-06 2006-02-16 Bayer Healthcare Ag Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen
JP4958787B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
WO2006099958A1 (fr) 2005-03-24 2006-09-28 Bayer Healthcare Ag Utilisation de 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines substituees pour traiter les lesions de reperfusion et les dommages de reperfusion
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
AU2007246172A1 (en) 2006-04-28 2007-11-08 Avexa Limited Integrase inhibitors 3
WO2008008059A1 (fr) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Agents anti-cancer et leurs utilisations
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056739A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
JP2008266143A (ja) 2007-04-16 2008-11-06 Santen Pharmaceut Co Ltd アデノシン誘導体を有効成分として含有する緑内障治療剤
DE102007035367A1 (de) * 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036075A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Ag Prodrugs und ihre Verwendung
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
JP2011520997A (ja) 2008-05-29 2011-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ２−アルコキシ置換ジシアノピリジン類およびそれらの使用
DE102008062566A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Aminosäureester-Prodrugs und ihre Verwendung
DE102008062567A1 (de) * 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
HUE028068T2 (en) * 2009-05-01 2016-11-28 Inotek Pharmaceuticals Corp A method for reducing the pressure in a human patient

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007036076A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102008062561A1 (de) * 2008-12-16 2010-06-24 Maxon Motor Ag Bausatz für einen Elektromotor mit einem Drehwinkelgeber

Also Published As

Publication number Publication date
EP2611415B1 (fr) 2016-02-24
PH12013500416A1 (en) 2013-04-15
RS54743B1 (sr) 2016-10-31
CY1117458T1 (el) 2017-04-26
EA028411B1 (ru) 2017-11-30
HK1188138A1 (en) 2014-04-25
CN103249400A (zh) 2013-08-14
CL2013000599A1 (es) 2013-08-09
MX2013002396A (es) 2013-04-03
DK2611415T3 (en) 2016-05-23
BR112013005224A2 (pt) 2016-05-03
CL2016001164A1 (es) 2016-12-23
SI2611415T1 (sl) 2016-06-30
ES2570659T3 (es) 2016-05-19
TW201212926A (en) 2012-04-01
PL2611415T3 (pl) 2016-08-31
JP2013536819A (ja) 2013-09-26
UA111947C2 (uk) 2016-07-11
US20150306084A1 (en) 2015-10-29
ZA201302340B (en) 2015-11-25
HUE027295T2 (en) 2016-10-28
MA34489B1 (fr) 2013-08-01
HRP20160532T1 (hr) 2016-06-17
TWI516266B (zh) 2016-01-11
CR20130094A (es) 2013-07-01
EP2611415A1 (fr) 2013-07-10
AP2013006753A0 (en) 2013-02-28
WO2012028585A1 (fr) 2012-03-08
EA201300310A1 (ru) 2013-08-30
SG187974A1 (en) 2013-04-30
MY160383A (en) 2017-03-15
NZ607624A (en) 2014-10-31
US9040566B2 (en) 2015-05-26
US20130210797A1 (en) 2013-08-15
CA2809700A1 (fr) 2012-03-08
US20120058983A1 (en) 2012-03-08
JP5875585B2 (ja) 2016-03-02
AU2011298430B2 (en) 2015-02-26
CN103249400B (zh) 2015-04-22
AU2011298430A1 (en) 2013-03-21
KR20140091457A (ko) 2014-07-21

Similar Documents

Publication Publication Date Title
ZA201404121B (en) Compositions for the treatment of dry eye
EP2621499A4 (fr) Méthodes de traitement de maladies allergiques
ZA201302340B (en) Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension
IL207397A0 (en) Difluorobiphenylamide derivtives for the treatment of ocular hypertension
WO2011163452A8 (fr) Traitement des troubles de la surface des yeux
ZA201403430B (en) 4-pregenen- 11ss -17 - 21-triols-3, 20- dione derivatives for the treatment of ocular conditions
EP2623494A4 (fr) Agent pour le traitement de maladies oculaires
ZA201303829B (en) 2-piperazin-1-yl-4h-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections
PL2838417T3 (pl) Urządzenie i sposób do nieinwazyjnego pomiaru stanu napięcia, biochemicznych i lepkosprężystych właściwości powierzchni biologicznych tkanek miękkich
IL230960A0 (en) A device for the treatment of eye disease
PL2538918T3 (pl) Cytocholina do leczenia jaskry
IL236637A0 (en) Difluorolactam compounds as selective ep4 receptor agonists for use in the treatment of ep4-mediated conditions and diseases
IL230959B (en) A device for the treatment of eye disease
IL250077A0 (en) Lactam compounds as selective agonists for the ep4 receptor for use in the treatment of ep4-mediated diseases and conditions
EP2734188A4 (fr) Compositions et procédés pour le traitement d'allergies de la surface oculaire
IL205774A0 (en) Novel compounds for the treatment of glaucoma and ocular hypertension
PT2456445E (pt) Agente para o tratamento de condições da pele
IL221469A0 (en) A3ar agonists for the treatment of uveitis
HK1188955A (en) Methods for treating diseases of the retina
GB0911577D0 (en) Compositions for the treatment of dry eye
IL223055A0 (en) Compositions for the treatment of gynaecological disorders
GB0901727D0 (en) The treatment of ophthalmic diseases
GB0801511D0 (en) The treatment of ophthalmic diseases
ZA200907826B (en) Neramexane for the treatment of nystagmus
HK1192471A (en) Compositions, devices and methods of use thereof for the treatment of cancers